Literature DB >> 15181652

Enhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (Kava-kava).

Richard Thompson1, Willibald Ruch, Rüdiger U Hasenöhrl.   

Abstract

The acute effects of the herbal anxiolytic Kava-kava (Piper methysticum G. Forster) on emotional reactivity and cognitive performance were investigated in a double-blind randomized placebo-controlled trial involving healthy volunteers. Subjects' reports of mood change were assessed with the state-trait-cheerfulness-inventory, which measures the three concepts of cheerfulness, seriousness and bad mood as both traits and states. Cognitive performance was examined with the Sperling partial report and the Sternberg item recognition task, which were used as an index for visual attention and short-term memory processing. The intake of a single dose of Kava extract (300 mg; p.o.) led to an increase in state cheerfulness, while the phytopharmacon did not influence state seriousness and bad mood. The mood-elevating effects of Kava were most prominent in trait cheerful subjects, indicating that trait cheerfulness moderated the drug-induced increase in cheerful mood. Furthermore, Kava improved the accuracy and the speed of performing the partial report and the item recognition task, indicative of a beneficial effect of the phytopharmacon on visual attention and short-term memory retrieval, respectively. Thus, unlike conventional benzodiazepine-type anxiolytics, which tend to impair cognitive performance and to increase the occurrence of negative affective states, Kava is a potent anxiolytic agent, which, additionally, can facilitate cognitive functioning and can increase positive affectivity related to exhilaration. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15181652     DOI: 10.1002/hup.581

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  7 in total

1.  Effects of a mood-enhancing intervention on subjective well-being and cardiovascular parameters.

Authors:  Ilona Papousek; Günter Schulter
Journal:  Int J Behav Med       Date:  2008

Review 2.  Management of anxiety and sleep disorders: role of complementary and alternative medicine and challenges of integration with conventional orthodox care.

Authors:  Martins Ekor; Oluyomi S Adeyemi; Chiagoziem A Otuechere
Journal:  Chin J Integr Med       Date:  2012-12-29       Impact factor: 1.978

3.  The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum.

Authors:  J Sarris; D J Kavanagh; G Byrne; K M Bone; J Adams; G Deed
Journal:  Psychopharmacology (Berl)       Date:  2009-05-09       Impact factor: 4.530

4.  A re-evaluation of kava (Piper methysticum).

Authors:  E Ernst
Journal:  Br J Clin Pharmacol       Date:  2007-06-06       Impact factor: 4.335

5.  Assessing the Temperamental Basis of the Sense of Humor: Adaptation of the English Language Version of the State-Trait Cheerfulness Inventory Long and Standard Form.

Authors:  Jennifer Hofmann; Hugo Carretero-Dios; Amy Carrell
Journal:  Front Psychol       Date:  2018-11-27

6.  Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial.

Authors:  Karen M Savage; Con K Stough; Gerard J Byrne; Andrew Scholey; Chad Bousman; Jenifer Murphy; Patricia Macdonald; Chao Suo; Matthew Hughes; Stuart Thomas; Rolf Teschke; Chengguo Xing; Jerome Sarris
Journal:  Trials       Date:  2015-11-02       Impact factor: 2.279

7.  Driving following Kava Use and Road Traffic Injuries: A Population-Based Case-Control Study in Fiji (TRIP 14).

Authors:  Iris Wainiqolo; Berlin Kafoa; Bridget Kool; Elizabeth Robinson; Josephine Herman; Eddie McCaig; Shanthi Ameratunga
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.